Ivabradine Tablet, Film Coated
Product Images NDC 46708-680

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 46708-680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ivabradine-5mg (Ivabradine 5mg)

Ivabradine Tablets 5 mg film-coated tablets packaging label. The label indicates the product contains 5 mg ivabradine as hydrochloride per tablet, is intended for oral use, and includes 60 tablets per package. Manufactured by Alembic Pharmaceuticals Limited, the label notes storage instructions, child-resistant packaging, and that it is a prescription drug.*

FDA Label Image

Ivabradine-7-5mg (Ivabradine 7 5mg)

Ivabradine Tablets 7.5 mg film-coated tablets label from Alembic Pharmaceuticals Limited. The label states the strength as 7.5 mg and includes storage instructions, manufacturer information, and a barcode. The package contains 60 film-coated tablets for oral use, marked as Rx only.*

FDA Label Image

Ivabradine-fig2.jpg (Ivabradine Fig2)

A chart showing the fold change and 90% confidence intervals for pharmacokinetic (PK) measures such as Cmax and AUC of ivabradine when co-administered with various substances, including CYP3A4 inhibitors, CYP3A4 inducer, and other drugs. The chart also provides dosing recommendations based on these changes, ranging from contraindicated to no dose adjustment needed.*

FDA Label Image

Ivabradine-fig3.jpg (Ivabradine Fig3)

A line graph comparing the proportion of heart failure hospitalization or cardiovascular death over time (months) between Ivabradine and placebo groups. The graph shows two curves representing the proportion (%) over a 36-month period, with Ivabradine exhibiting a lower proportion than placebo. Below the graph, the number of subjects at risk for each group is presented at various time points.*

FDA Label Image

Ivabradine-figure4 (Ivabradine Figure4)

A forest plot comparing the hazard ratio (HR) and 95% confidence intervals (CI) for Ivabradine versus placebo across various demographic and clinical subgroups. The categories include age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA class, baseline left ventricular ejection fraction, baseline beta blocker and aldosterone antagonist use, diabetes, hypertension, and an overall summary. Each subgroup shows the percentage of the total population, the numbers in the Ivabradine and placebo groups, and visual indicators of HR favoring Ivabradine or placebo.*

FDA Label Image

Ivabradine-structure.jpg (Ivabradine Structure)

Chemical structure of Ivabradine hydrochloride, showing the molecular arrangement including methoxy groups, a lactam ring, and a substituted benzazepine system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.